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Background and aims: Familial hypercholesterolemia (FH) is a life-threatening disease, characterized by
elevated LDL-C levels and a premature, increased risk of coronary heart disease (CHD) that is globally
underdiagnosed. The percentage of patients with possible or probable FH in various countries was
examined in the Dyslipidemia International Study (DYSIS).
Methods: DYSIS is a multinational, cross-sectional observational study of 54,811 adult outpatients treated
with statin therapy. The percentages of patients with high levels of LDL-C, and with possible or probable
FH, were assessed using the Dutch scoring method for FH across 29 countries, in age subgroups for the
analysis population and among diabetes patients.
Results: Despite statin therapy, 16.1% (range 4.4e27.6%) of patients had LDL-C >3.6 mmol/L (140 mg/dL)
across countries and the prevalence of possible FH was 15.0% (range 5.5e27.8%) and 1.1% (range 0.0
e5.4%) for probable FH. The highest percentages of probable FH occurred in Egypt (5.4%), the Baltic states
(4.2%), Russia (3.2%), and Slovenia (3.1%), with the lowest rates in Israel (0.0%), Canada (0.2%), and
Sweden (0.3%). Rates of FH were the highest in younger patients (45e54 years) for secondary prevention,
regardless of the presence/absence of diabetes.
Conclusions: Despite statin therapy, high LDL-C levels and rates of possible and probable FH were
observed in some countries. The prevalence of FH was the highest in younger age patients, and >60% of
patients with probable FH displayed CHD. Earlier diagnosis and treatment of patients with FH are needed
to reduce CHD risk in these patients.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Familial hypercholesterolemia (FH) is a serious, life-threateninggical and Biomolecular Sci-
G. Balzaretti, 9-20133, Milan,
atapano).
Ireland Ltd. This is an open accessdisease [1e4], and is widely underdiagnosed [3,4]. It is clear that
only rigorous screening in the population can identify affected
patients and could reduce the high risk of cardiovascular disease
(CVD) in these patients. FH is caused by a group of inherited genetic
disorders in low-density lipoprotein (LDL) catabolism, attributed to
defects in the LDL-receptor, apolipoprotein B, proprotein con-
vertase subtilisin/kexin type 9 (PCSK9), and LDL receptor adaptor
protein 1 (also known as autosomal dominant hypercholesterole-
mia), that result in elevated LDL-cholesterol (C) levels, as well as aarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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disease (CHD) [1e4]. In most populations worldwide [1], hetero-
zygous (He) forms are more common than previously thought (1 in
250) and, as a consequence, the homozygous (Ho) form of FH af-
fects approximately 1 in 160e300,000 in most populations
worldwide [1]. In most European countries, a minority of patients
(<1%) have been identiﬁed with FH, while in other countries the
incidence is much higher [2].
Premature cardiovascular disease is common in HoFH and HeFH
patients, with an increased risk of CVD, including stroke and
myocardial infarction, occurring at young ages. Given the increased
lifetime CHD risk associated with FH, lifestyle intervention and
appropriate lipid-lowering therapy are recommended that can
greatly reduce this risk [5]. Treatment recommendations include
long-term cholesterol-lowering therapy for all adult HeFH and
HoFH patients to reduce LDL-C by  50%, and more intensive lipid-
lowering therapy to achieve levels of LDL-C <1.8 mmol/L (70 mg/
dL) and <2.6 mmol/L (100 mg/dL) and non-HDL-C <3.4 mmol/L
(130 mg/dL) when needed [1e3,5e8].
Diagnosis of FH is based on genotyping and/or evaluation in
clinical practice that takes into account LDL-C levels, the presence
of premature CHD in patients or in ﬁrst-degree relatives, as well as a
clinical examination for tendon xanthomata and arcus cornealis (at
a young age) [2]. While only a genetic evaluation can conﬁrm a
diagnosis of FH, estimation based on scoring systems is widely
accepted as well. The Dutch Lipid Network scoring method [9] is
recommended in recent guidelines for FH diagnosis [10]. Other
combined methods, such as the Simon Broome register group
estimation [11], are similar to the Dutch scoring approach. Results
from global registries, surveys, observational studies or other ana-
lyses reporting on the prevalence of FH are limited [12]. Hence, we
sought to evaluate the percentage of patients with high LDL-C
levels and possible or probable FH in various countries using the
Dutch scoring method in the population of >50,000 adult out-
patients treated with statins in the previously reported multina-
tional, cross-sectional Dyslipidemia International Study (DYSIS)
[13,14].
2. Materials and methods
2.1. DYSIS patient enrollment
This is an analysis of the population previously reported in
DYSIS, an epidemiological, cross-sectional, multicenter study
[13,14]. The study was conducted in Europe, China, Canada, Russia,
South and northern Africa, as well as the Middle East (Austria,
Belgium, Baltic states, Canada, China, Germany, Denmark, Egypt,
France, Greece, United Arab Emirates, Israel, Ireland, Italy, Lebanon/
Jordan, Netherlands, Norway, Portugal, Russia, Saudi, Slovakia,
Slovenia, South Africa, Spain, Sweden, United Kingdom). The ﬁrst
patient was enrolled in 2008 and the last in 2013. A total of 6e10
statin-treated outpatients were enrolled consecutively per center
(n ¼ 60,768). Patients on combination therapy, such as statin plus
ezetimibe, niacin, ﬁbrates and bile-acid sequestrants, were also
included. Informed consent was obtained from all patients, and the
local ethical review committees approved the study protocol. On-
site visits were performed to ensure the correctness of collected
data. Source documentation and data accuracy was veriﬁed by site
visits in randomly selected sites. Participants were enrolled based
on the following criteria: 45 years old, treated with statins within
6e12 months, and had at least one fasting blood lipid proﬁle
available while on statins for 3 months within that 6e12 month
time period. LDL-C was assessed per standard procedure in each
country. Details are described elsewhere [13]. At the single exam-
ination visit, the full lipid proﬁle, anthropometric parameters, andthe patients' clinical history including premature cardiovascular
disease in ﬁrst-degree relatives were assessed.
2.2. Data collection
Patient data were documented using local language case report
forms and entered into one central database housed and managed
at the Institut für Herzinfarktforschung, Ludwigshafen, Germany.
Serum lipid levels were determined based on the patients' most
recent blood tests (within 6e12 months, but at least three months
on statin therapy). The lipid-lowering regimen used by each patient
at the time of lipid measurement was also recorded. In particular,
information was collected pertaining to statin type, dose level, and
other lipid-modifying therapies utilized in combination with
statins.
2.3. Diagnosis of FH and methods
To evaluate the rate of patients with possible FH per country, we
based our analysis on the Advanced method for the identiﬁcation of
patients with inherited hypercholesterolemia as recommended by
the recent European Society of Cardiology/European Atheroscle-
rosis Society (ESC/EAS) guidelines for the management of dyslipi-
daemias [10]. A stepwise approach was subsequently applied. First,
patients with high LDL-C despite statin treatment were identiﬁed.
While baseline values of LDL cholesterol before treatment were not
available, we estimated an approximate reduction of LDL-C by 30%
(corresponding to the correction applied in this analysis). Therefore
in treated patients who had an LDL-C >3.6 mmol/L (140 mg/dL),
baseline values were correspondingly estimated to be > 5.2 mmol/L
(200 mg/dL). A blood cholesterol of >5.2 mmol/L (200 mg/dL) is
deﬁned as a diagnostic criterion for FH by the authors of the Eu-
ropean guidelines [10]. As a second step, we applied the Dutch
scoring methods to all patients included in DYSIS, when completed
information on the following criteria was available including age,
gender, premature coronary artery disease (CAD) (male before 55,
women before 60 years of age), ﬁrst-degree relative known with
premature CAD, and LDL-C values (Table 1). The sample represents
90.2% (n¼ 54,811) of the entire patients included in DYSIS, while in
9.8% one or more of the above parameters was missing. Parameters
assessed were LDL-C, ﬁrst-degree relative premature CAD, prema-
ture CAD and extra-coronary vascular disease in the patients
themselves. Data on ﬁrst-degree relative LDL-C and physical ex-
aminations for tendon xanthomata and arcus cornealis were not
collected in DYSIS.
2.4. Statistical analysis
Descriptive analysis was performed using standard statistical
methods. Values are displayed as medians and inter-quartile range
(IQR) or percentages (%). Statistical testing for comparison was
performed with the Kruskal-Wallis or Chi-square tests. The prev-
alence of potential FH was categorized by age using the Cochran-
Armitage-test for trend. LDL-C as a continuous variable was trans-
formed into a categorical one, for the identiﬁcation of patients
possibly suffering from FH. Additionally, age was further assessed
per ten-year intervals. Statin equivalence was assessed using the
equation on the relative LDL-C-lowering efﬁcacy published by the
FDA (http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm#
Relative) [15]. In brief, an atorvastatin equivalent of 20 mg was
considered to be equivalent to pravastatin 80 mg, rosuvastatin
5 mg, and simvastatin 40 mg, while atorvastatin 10 mg was
equivalent to pravastatin 40 mg, and simvastatin 20 mg. A p-value
<0.05 was considered statistically signiﬁcant. SAS version 9.3 was
used for all calculations. Analyses were performed at the Institut
Table 1
Diagnostic criteria for the clinical diagnosis of HeFH [10].
Criteria Score
Family history First-degree relative known with premature CAD &/or ﬁrst degree relative with LDL-C >95th centile 1
First-degree relative with TX &/children <18 with LDL-C >95th centile 2
Clinical history Patient has premature CAD 2
Patient has premature cerebral/peripheral vascular disease 1
Physical examination Tendon xanthomatas (TX) 6
Arcus cornealis below the age of 45 years 4
LDL-C >8.5 mmol/L (~330 mg/dL) 8
6.5e8.5 mmol/L (~250e329 mg/dL) 5
4.9e6.5 mmol/L (~190e249 mg/dL) 3
4.0e4.9 mmol/L (~155e189 mg/dL) 1
Clinical diagnosis Deﬁnite FH Score >8
Probable FH Score 6-8
Possible FH Score 3-5
CAD, coronary artery disease; LDL-C, low density lipoprotein cholesterol; TX, tendon xanthomatas; FH, familial hypercholesterolemia. To convert SI units to conventional units
divide by 0.0259 for cholesterol.
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3. Results
A total of 54,811 patients from 29 countries were included in the
analysis. Of these, 83.8% of patients were categorized with a clinical
diagnosis as 0e2 points for FH, 15% as 3e5 points for possible FH,
and 1.2% as >6 points for probable FH (Table 2). The mean age of all
patients across categories was 65 years, 45.4% of the subjects were
females, and the mean baseline levels of LDL-C, HDL-C and total
cholesterol were 3.3 mmol/L (129 mg/dL), 1.3 mmol/L (50 mg/dL)
and 4.6 mmol/L (178 mg/dL), respectively. Higher levels of BMI,
LDL-C, total cholesterol and triglycerides were present in the
probable FH (>6 point) group compared with the FH 0e3 and 3e5
points groups (p < 0.0001 for all). Baseline comorbidities for all
patients and those with possible and probable FH are provided by
country in Supplementary Tables 1, 2 and 3, respectively.
Ischemic cardiovascular diseases occurred at a statistically
signiﬁcantly and clinically-relevant higher level in the group of
patients with probable FH compared with the total population
(Table 2). Ischemic heart disease was most pronounced with 60.1%
vs. 38.8% in the total population (p < 0.0001), and similarTable 2
Characteristics and comorbidities of patients depending on estimated probability of FH.
Median (range) Total 0e2 points
n ¼ 54,811 n ¼ 45,936
Age, years 65 (57e72) 65 (58e73)
Female % 45.4 44.0
BMI, kg/m2 27 (24e30) 26 (24e30)
Total cholesterol, mmol/dL 4.6 (3.9e5.4) 4.4 (3.7e5.1)
LDL-C, mmol/dL 3.3 (2.6e4.2) 3.1 (2.5e3.8)
Triglycerides, mmol/dL 1.5 (1.1e2.1) 1.5 (1.0e2.1)
FPG, mmol/dlb 5.8 (5.1e7.0) 5.8 (5.1e7.0)
SBP, mmHg 130 (120e140) 130 (120e140)
DBP, mmHg 80 (70e85) 80 (70e84)
Hypertension, %c 78.2 78.7
Ischemic heart disease, % 38.8 38.7
Cerebrovascular disease, % 13.6 13.7
Peripheral artery disease, % 6.0 5.8
Congestive heart failure, %d 7.8 7.7
Diabetes mellitus, % 40.2 41.3
BMI, body mass index; FPG, fasting plasma glucose; LDL-C,low-density lipoprotein choles
Values are reported as median and interquartile range or percentages.
To convert SI units to conventional units divide by: 0.0259 for cholesterol, 0.0113 for tri
a Chi-Square or Kruskal Wallis test; p-values are 3-way comparisons between FH grou
b FPG availability: 70.8% (36.76/51.93).
c BP 140/90 mmHg or use of antihypertensive medication.
d Congestive heart failure includes patients with chronic heart failure (NYHA graded 2differences were observed for peripheral artery disease (PAD)
(12.8% vs. 6.0%) and cerebrovascular disease (17.3% vs. 13.6%,
p < 0.001). Strikingly, we also detected a difference in the preva-
lence of congestive heart failure (14.9% vs. 7.8%, p < 0.0001). In
contrast, there were no relevant differences detected for those with
hypertension and diabetes, regardless of the potential FH status.
Themost widely used statin doses were atorvastatin equivalents
of 10 mg per day in 41.2% and 20 mg in 37.7% (11.1% 5 mg, 8.3%
40 mg, and 1.8% 80 mg) of patients (Table 3). There were also a
small proportion of patients (11.9%) treated with combination
therapy (6.6% with ezetimibe, 4.3% with a ﬁbrate, 0.7% with niacin,
and 0.3% with a bile acid sequestrant). There were no differences in
the use of concomitant medications between the FH groups
(Table 3).
Despite statin therapy, evaluating the percentage of patients
suffering from high LDL-C levels, 16.1% (n ¼ 8832) of the patients
displayed LDL-C levels >3.6 mmol/L (140 mg/dL), 8.2% (n ¼ 4500)
had LDL-C >4.1 mmol/L (160 mg/dL), 2.5% (n ¼ 1366) had LDL-C
>4.9 mmol/L (190 mg/dL) and 0.8% (n ¼ 427) had LDL-C
>5.7 mmol/L (220 mg/dL). The range was 4.7e27.6% among the
different countries. The highest prevalence of >25% with high LDL-
C on statin treatment was found in the Baltic states (Estonia, Latvia,3e5 points >6 points p-valuea
n ¼ 8219 n ¼ 656
60 (53e68) 56 (52e62) <0.0001
52.0 54.7 <0.0001
27 (24e30) 28 (25e32) <0.0001
6.2 (5.5e6.7) 7.4 (6.6e8.2) <0.0001
5.4 (5.0e5.9) 6.9 (6.3e7.9) <0.0001
1.7 (1.3e2.4) 2.1 (1.5e2.8) <0.0001
5.7 (5.1e7.0) 5.7 (5.0e6.9) ns (0.12)
132 (120e142) 140 (130e150) <0.0001
80 (75e88) 80 (79e90) <0.0001
74.8 84.0 0.0001
38.0 60.1 <0.001
12.6 17.3 <0.0001
6.3 12.8 <0.0001
7.8 14.9 <0.0001
34.5 33.8 <0.0001
terol; ns,non-signiﬁcant; SBP, systolic blood pressure; DBP, diastolic blood pressure.
glycerides, and 0.0555 for fasting glucose.
ps (0e2, 3e5, 6 þ points).
e3), as diagnosed by the treating physician.
Table 3
Cardiovascular medications of patients depending on estimated probability of FH.
% Total 0e2 points 3e5 points >6 points
n ¼ 54,811 n ¼ 45,936 n ¼ 8219 n ¼ 656
Beta-blockers 31.4 31.9 28.1 38.9
Calcium channel blockers 30.6 31.3 26.9 29.9
Diuretics 22.2 22.6 19.8 26.7
Angiotensin converting enzyme inhibitors 27.5 27.6 26.6 36.4
Angiotensin receptor blockers 26.1 26.9 22.0 23.7
Aspirin 55.7 57.1 47.8 58.4
Clopidogrel 14.0 14.3 12.2 19.7
Statin dosea mg/day (SD) 16.2 (12.4) 15.9 (12.1) 17.0 (13.6) 23.1 (18.2)
a Calculated in atorvastatin equivalent mmol/L (mg/dL).
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prevalence of<10% in Belgium (8.7%), Canada (4.7%), Denmark 6.3%,
United Arab Emirates (5.2%), Israel (6.3%), Ireland (9.0%),
Netherlands (8.8%), Saudi (5.8%), Sweden (6.6%), and UK (5.1%). Of
note, 5 countries/regions displayed a high percentage (4.0%) of
high LDL-C levels (>4.9 mmol/dL [190 mg/dL]) including the Baltic
states 9.0%, Egypt (5.2%), Greece (4.5%), Russia (4.3%), and Spain
(4.0%). These results were derived before correcting for LDL-C.
According to the Dutch scoring method, FH was considered
possible in individuals with 3e5 score points and probable in in-
dividuals with 6e8 score points [7]. After correcting for the statin
treatment effect (estimated naïve LDL-C), 15.0% (range 5.5e27.8%)
of patients could possibly and 1.1% (range 0.0e5.4%) could probably
suffer from FH (Figs. 1 and 2). The highest levels of probable FH
were found in Egypt (5.9%), the Baltic states (4.9%), Russia (3.2%),
and Slovenia (3.4%), lowest in Israel (0.0%), Canada (0.2%), and
Sweden (0.3%) (Fig. 2).
An age-directed analysis was performed at 10-year intervals.
The prevalence of possible or probable FH was highest in the
youngest age group of 45e54 years (27.5% and 2.9%, respectively;
n ¼ 9488) and declined thereafter to 15.5% and 1.2% in the 55e64
years (n ¼ 18,058) group, 10.8% and 0.5% in 65e74 years
(n ¼ 17,796) and 9.3% and 0.4% in patients 75 years of age
(n ¼ 9469). This distribution was highly signiﬁcant (p for trend15.0
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Fig. 1. Percentage of statin-treated patients potentially suffering from FH per count<0.0001). The percentage of patients suffering from possible or
probable FH, further stratiﬁed as primary and secondary preven-
tion, conﬁrmed the observation of the highest prevalence rate of FH
in younger patients, but more speciﬁcally in those who already
suffered from an ischemic heart or cerebrovascular disease event
(Fig. 3 and Supplementary Table 4). However, within this study,
only statin-treated patients and not the general population were
included, which could create a selection bias.
An age-related analysis among the diabetes patients was also
performed. Similarly, the prevalences of possibly or probably FH in
diabetics were also more pronounced in the younger age group
(Fig. 4). However, there was little difference between patients with
and without diabetes (Supplementary Table 5).
4. Discussion
In this multinational study of 54,811 patients enrolled between
2008 and 2013, we found a large proportion of patients with high
LDL-C levels of >4.9 mmol/L (190 mg/dL) that ranged from 0.4 to
9.0% per country, despite statin therapy with atorvastatin equiva-
lents of 10 and 20 mg in ~40% of the patients for 3 months.
Screening for FH according to criteria set by the EAS/ESC guidelines
revealed that 15.1% of individuals could possibly, and 1.1% may
probably suffer from a genetic disposition to elevated blood13.8
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Fig. 2. Percentage of statin-treated patients probably suffering from FH per country. Probable FH (6e8 score points) category. Baltic states: Estonia, Latvia, Lithuania.
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Fig. 3. Distribution of patients potentially suffering from FH for age groups 45e54, 55e65, 65e74, and 75 years, and stratiﬁed for primary and secondary prevention. (A)
Possible FH deﬁned as 3e5 score points; (B) probable FH deﬁned as 6e8 score points.
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Fig. 4. Distribution of patients potentially suffering from FH for age groups 45e54, 55e65, 65e74, and 75 years, and stratiﬁed for diabetes mellitus. (A) Possible FH deﬁned
as 3e5 score points; (B) probable FH deﬁned as 6e8 score points.
A.L. Catapano et al. / Atherosclerosis 252 (2016) 1e86cholesterol levels. Prevalence for possible and probable FH is re-
ported for the ﬁrst time, especially for China (n ¼ 23,973), Egypt
(n ¼ 1322), and Austria (n ¼ 753) among several other countries.
High LDL-C values can be related to genetic, environmental, and
secondary causes. These include (1) loss-of-function poly-
morphisms in the LDL-receptor, adaptor protein, and ApoB, and
gain of function polymorphisms in PCSK9 [2]; (2) environmental
factors such as a high-density calorie-rich diet of saturated fat or
trans-fatty acids [16,17]; (3) chronic use of cholesterol-increasing
medication (e.g., corticosteroids) [18]; and (4) endocrine diseases,
with hypothyroidism being the most prevalent [19]. While dietary
factors may account for high LDL-C levels, this is more limited to
certain age groups; whereas genetically-related, high blood
cholesterol levels occur at birth and are life-long [20].
Consequences of hyperlipidemia include the early development
of atherosclerotic disease leading to myocardial infarction [2], with
subsequent remodeling of the left ventricle that can result in
congestive heart failure [21,22]. This widely under-appreciated fact
is supported by ﬁndings from a follow-up analysis of the WOSCOPS
trial [23]. In the original 5-year period of the trial, pravastatin
lowered LDL-C by 26% and the risk of fatal or nonfatal coronary
events by approximately 30% compared with placebo; whereas in a
10-year follow up of the study in which patients in the original
statin and placebo groups were treated equivalently with statins to
similar LDL-C levels, there was a signiﬁcantly greater reduction inmajor cardiovascular events and heart failure in those in the orig-
inal pravastatin group who received treatment during the full 10-
year period compared with those in the less-treated, original pla-
cebo group. The data presented in our study indicate a similar trend
with an approximate 2-fold increase in not only ischemic diseases,
but also in CHF in the group with the highest probability of FH
(Table 2). In patients with FH, the elevation in serum levels of LDL-C
occurs from the moment of conception and greatly increases the
likelihood of developing atherosclerotic disease at a young age [2].
Both the effect of developing and reducing CVD risk is related to
the absolute amount of blood cholesterol over time. The clinical
implications of this can be extreme since homozygous FH patients
can suffer from major vascular events early in childhood and, if
untreated, can result in mortality by the age of 30 [1]. Mendelian
randomization studies have conﬁrmed that long-term exposure to
even small elevations in blood cholesterol levels can substantially
increase CHD risk over time [20] and is consistent with the obser-
vations in our epidemiologic study indicating a signiﬁcantly higher
burden of CVD in patients probably suffering from FH.
The EAS called for nationwide screening of FH in a recent po-
sition paper [2]. Similarly, the expert panel of the US National Lipid
Association documented an under diagnosis of FH and a need for
better screening [7]. The data presented herein indicate large
regional differences in percentages of probable FH ranging from
0.0% in Israel to 5.4% in Egypt, 4.2% in the Baltic states, and 3.2% in
A.L. Catapano et al. / Atherosclerosis 252 (2016) 1e8 7Russia. To our knowledge, this very high rate observed for Egypt is a
novel ﬁnding. These differences may be attributed to the founder
effect or consanguinity, and/or selection of patients by high LDL-C
and treatment. Our study extends the results of a previously re-
ported analysis of data in coronary patients from 24 European
countries (EUROASPIRE IV) [24] which documented high age-
standardized rates (>10%) of potential FH in Bosnia, Ireland,
Latvia, Lithuania, Poland, Russia and Serbia, as well as regional
variation. Although the data in our analysis were not determined in
study patients who had been hospitalized for a coronary event as in
the EUROASPIRE survey, similar rates of FH were observed in the 2
studies. EUROASPIRE IV reported a 7.2% rate for probable FH and a
31.6% rate for possible FH in coronary post-PCI patients, whereas
our analysis of DYSIS revealed a 6.4% rate for probable FH and a
42.5% rate for possible FH in patients 45e54 years of age who did
suffer from a prior cardiovascular event. Moreover, both studies
showed that the greatest prevalence of FH occurred in younger
patients (<50 years of age) and highlight the need for early
detection given the life-long elevated LDL-C and premature CHD in
these high risk patients. The results of these studies indicate a need
for further analyses of FH worldwide and, importantly, better
screening and therapeutic action in these patients. In this context, it
is striking that patients with >6 score points in our analysis man-
ifested evidence of atherosclerotic disease with a high prevalence,
but were not treated in a manner different from that of the general
analysis population, similar to observations in EUROASPIRE IV [24].
The continuum of CV disease burden can be substantially
reversed by effective lipid-lowering therapy, as proven for statin
therapy in numerous trials [25], and for ezetimibe in the recently
reported IMPROVE-IT outcomes trial [26] [27], while the effect of
PCSK9 inhibitors on cardiovascular outcomes is being evaluated in
ongoing clinical trials [28,29]. Optimal treatment of FH patients has
been addressed in respective guidelines and consensus statements
[1,4,7,10] and follows an approach of treatment goals [1,2] or a50%
reduction of LDL-cholesterol and if additional LDL-C lowering is
needed, combination therapy can be considered [7,30]. After cor-
recting for treatment effect on the basis of LDL-C lowering efﬁcacy,
16% of the patients included in our study had LDL-C levels
>3.6 mmol/L (140 mg/dL), and <2% were treated with a high-dose
statin equivalent and ~12% with a statin/non-statin combination.
Based on the variability of LDL-C lowering response demonstrated
for high-dose statin therapy in achieving optimal LDL-C lowering
[31], combination therapy may be needed in high-risk patients in
order to achieve treatment goals. The authors of the EAS consensus
statement [2] highlight the need for intensiﬁed lipid-lowering
therapy (statins in the highest tolerated dose, followed by ezeti-
mibe and bile acid sequestrants) in an age-dependent manner to
reduce risk levels to those of primary prevention in the general
population. We could not identify differences in statin-treatment
among FH risk groups, nor in the utilization of antihypertensive
or antithrombotic medications which were used at a strikingly low
level given the manifestation of ischemic heart disease in nearly
two thirds of the patients probably suffering from FH (39% beta
blockers, 20% clopidogrel). This is further in line with data from
EUROASPIRE IV that showed no signiﬁcant difference in the use of
drugs for cardiovascular disease between FH risk groups [24].
There are several limitations to our study. In DYSIS, physical
examination of the patients was not performed (e.g., xanthomas,
arcus cornealis). Thus, we were not able to include this information
in the score points and the assessment of FH may be somewhat
incomplete. However, this reﬂects a more conservative approach in
our analysis, that may even under-report the actual genetic rate of
FH patients, but nonetheless provides a better understanding
regarding the prevalence of this widely under-diagnosed and
under-treated disease. Further, we did not have baseline LDL-Clevels, but only treated LDL-C levels for 3 months and per-
formed a correction for this treatment effect. The correction of
baseline LDL-C values, estimated based on an approximate LDL-C
reduction of 30%, may also be a limitation particularly in coun-
tries with poor adherence to therapy. In DYSIS, cholesterol was not
assessed in a centralized lab, but was analyzed individually in the
countries as per daily practice routine, and thus may introduce
some variability in regional comparisons. We were also unable to
perform genetic screening in these respective countries and thus
could not conﬁrm our data by that means. Additionally, differences
in the various cholesterol guidelines used in the countries, tradi-
tions and lifestyles, as well as referral criteria from the many
different medical centers and physicians across the countries, may
have contributed to selection bias. It should also be considered that
the age-related analysis in this prospective registry study may be
somewhat over-estimated attributed to the selection criteria for
identiﬁcation of the young subjects whowere already being treated
with lipid-lowering therapy and may have had premature CHD;
however, these results are in line with prior reports of higher
prevalences for FH in younger patients. Our analysis was designed
to survey FH data for each country in general terms; thus, we did
not ascertain additional ethnic, religious and socioeconomic in-
formation which may vary among countries and is furthermore,
restricted from documentation in many European countries.
In conclusion, in this multinational study of 54,811 patients
including 23,973 individuals in China, we found unexpectedly high
rates of possible and probable FH, as well as very high cholesterol
levels in some countries, despite statin therapy. The highest rates of
FH were found in Egypt, the Baltic states, Russia, and Slovenia. The
prevalence of FH was more common in younger age groups, while
>60% of patients probably suffering from a genetic form of hyper-
cholesterolemia displayed CVD. Furthermore, treatment of these
potential FH patients with therapy equivalent to the LDL-C lowering
efﬁcacy of a mean atorvastatin dose of 20 mg in the majority of
patients (~38% on statins, ~12% on combination therapy) was
insufﬁcient to adequately control LDL-C levels. This suggests that
intensiﬁcation of therapy with higher statin doses and/or a greater
use of combination therapy is needed to further reduce the burden
of CVD (e.g., CHD or PAD) in these patients. Additionally, these data
are novel, providing ﬁrst-time reports of FH prevalence in many of
the countries, indicating the need for widespread screening and
treatment of FH patients with high blood cholesterol levels, in order
to reduce CVD risk. The scoring method used herein and proposed
by the EAS/ESC guidelines provides a tool for routine use in daily
clinical practice that could help to further reduce the burden of this
disease through earlier diagnosis and treatment of patients.
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